Astria Therapeutics Inc. has released its financial results for the first quarter ended March 31, 2025. The company reported a net loss of $33.7 million for the quarter, an increase from the $19.9 million net loss reported for the same period in 2024. The net loss per share was $0.58, compared to a net loss per share of $0.38 in the first quarter of 2024. The company had cash, cash equivalents, and short-term investments totaling $295.1 million as of March 31, 2025, down from $328.1 million at the end of 2024. Astria expects this cash position to be sufficient to fund its operations into mid-2027, supporting various program activities including the ALPHA-ORBIT Phase 3 trial for navenibart and the completion of the Phase 1a clinical trial for STAR-0310. In terms of business updates, Astria is currently enrolling patients in the pivotal Phase 3 ALPHA-ORBIT trial evaluating navenibart (STAR-0215) for hereditary angioedema. The company anticipates results from the ALPHA-SOLAR Long-Term Extension Trial in mid-2025 and results from the Phase 1a STAR-0310 healthy subject trial in the third quarter of 2025. Additionally, Astria announced its participation in upcoming investor conferences, including the Jefferies Global Healthcare Conference and the Oppenheimer Innovators in I&I Summit, both taking place in June 2025.